NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

中國的Emtricitabine/Tenofovir市場的相關調查報告書(2021年∼2025年)

Investigation Report on China's Emtricitabine/Tenofovir Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1010195
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Emtricitabine/Tenofovir市場的相關調查報告書(2021年∼2025年) Investigation Report on China's Emtricitabine/Tenofovir Market 2021-2025
出版日期: 2021年06月08日內容資訊: 英文 50 Pages
簡介

中國市場中Emtricitabine/Tenofovir的銷售量從2016年到2019年年年增加,2020年減少。減少的主要理由,是COVID-19流行,給予醫院的診斷、治療事業整體影響。

因為在2017年開始時,中國的醫療保險中包含了Emtricitabine/Tenofovir,2018年銷售量成為1,086萬人民幣,以年度成長率103%急速成長。銷售量2020年達成1,643萬人民幣,從2016年到2020年的年複合成長率為35.4%,非常高的水準。

本報告提供中國的Emtricitabine/Tenofovir市場的相關調查,市場規模和預測,價格,成長要素和機會等市場發展的影響因素分析,競爭情形,主要製造商/產品的簡介等資訊。

目錄

第1章 Emtricitabine/Tenofovir的相關概念

  • Emtricitabine/Tenofovir的適應症
  • 中國的Emtricitabine/Tenofovir的開發
  • 中國的Emtricitabine/Tenofovir的政府核准
  • COVID-19對中國的Emtricitabine/Tenofovir的銷售額的影響

第2章 中國的Emtricitabine/Tenofovir銷售(2016-2020)

  • Emtricitabine/Tenofovir的銷售量
    • 總銷售額
    • 各地區的銷售量
  • Emtricitabine/Tenofovir的銷售量
    • 整體銷售量
    • 各地區銷售量
  • 中國的各劑型Emtricitabine/Tenofovir銷售(2016-2020)
    • 錠劑
    • 其他的劑型分析

第3章 中國的主要Emtricitabine/Tenofovirmeka分析(2016-2020)

  • 主要的Emtricitabine/Tenofovirmeka的市場佔有率分析
    • 各銷售額市場佔有率調查
    • 各銷售量市場佔有率調查
  • Gilead Sciences Inc
    • 企業簡介
    • TRUVADA(Gilead Sciences Inc的Emtricitabine/Tenofovir)的中國的銷售
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    • 企業簡介
    • Clyke(Chia Tai Tianqing Pharmaceutical Group Co., Ltd.的Emtricitabine/Tenofovir的)中國的銷售

第4章 中國的各製造商Emtricitabine/Tenofovir的價格(2020-2021)

  • Gilead Sciences Inc(TRUVADA)
  • Chia Tai Tianqing Pharmaceutical Group Co.,Ltd。(Clyke)

第5章 中國的Emtricitabine/Tenofovir藥市場預測(2021-2025)

  • 中國的Emtricitabine/Tenofovir市場開發的有影響力的要素
    • COVID-19對中國的Emtricitabine/Tenofovir市場的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2106523

Emtricitabine/Tenofovir is the first HIV drug approved for prophylaxis. It was developed by Gilead Sciences Inc (the original drug is called TRUVADA). Its product was first approved in the United States in 2004 and was launched in China in 2012. TRUVAD was covered by China's national drug reimbursement list (NDRL) in 2017. As of the end of 2020, the manufacturers in the Chinese Emtricitabine/Tenofovir market are Gilead Sciences Inc and Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

According to CRI's market research, the sales value of Emtricitabine/Tenofovir in the Chinese market has increased year by year from 2016 to 2019, with a decline in 2020. The main reason for this decline is that the COVID-19 epidemic has affected the overall diagnosis and treatment business of the hospital. At the beginning of 2017, Emtricitabine/Tenofovir was included in China's Medical Insurance, so its sales value grew rapidly to CNY10.86 million in 2018, with an annual growth rate of 103%. The sales value of Emtricitabine/Tenofovir in the Chinese market reached CNY16.43 million in 2020 and the CAGR is 35.4% from 2016 to 2020, which is a very high level.

CRI predicts that with the increase in the number of AIDS patients in China, the sales of Emtricitabine/Tenofovir will also increase from 2016 to 2019. In 2019, the number of surviving HIV infections in China reached 958,000. In 2020, the number of surviving AIDS infections in China increased to 1.045 million, with an increase of 9%. The number of new infections will still show an increasing trend in the future. How to prevent new HIV infections has become the key to prevent and control the spread of AIDS. Therefore, sales in Emtricitabine/Tenofovir of the preventive HIV drugs will continue to increase. By 2020, 2 companies have launched generic versions of Truvada (Emtricitabine/Tenofovir) in China. The generic version from Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the first Chinese-made HIV combination tablet in the country. Qilu Pharmaceutical and Hisco Pharmaceutical are waiting for an Abbreviated New Drug Application (ANDA) approval for their generic version, and they will compete for the market after approval. The market competition of Emtricitabine/Tenofovir in China will become more intense. Sales prices are expected to continue to fall, and sales volume will increase accordingly. In addition, the effective alleviation of the COVID-19 epidemic during the period of 2021-2025 will also enable the sales of Emtricitabine/Tenofovir to have restorative growth.

Topics Covered:

  • The impact of COVID-19 on China's Emtricitabine/Tenofovir market
  • Sales value of China's Emtricitabine/Tenofovir 2016-2020
  • Competitive landscape of China's Emtricitabine/Tenofovir market
  • Prices of Emtricitabine/Tenofovir in China
  • Prices of Emtricitabine/Tenofovir in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Emtricitabine/Tenofovir market
  • Prospect of China's Emtricitabine/Tenofovir market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Emtricitabine/Tenofovir

  • 1.1 Indications for Emtricitabine/Tenofovir
  • 1.2 Development of Emtricitabine/Tenofovir in China
  • 1.3 Governmental Approval of Emtricitabine/Tenofovir in China
  • 1.4 The Impact of COVID-19 on Emtricitabine/Tenofovir sales in China

2 Sales of Emtricitabine/Tenofovir in China, 2016-2020

  • 2.1 Sales Value of Emtricitabine/Tenofovir
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Emtricitabine/Tenofovir
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Emtricitabine/Tenofovir by Dosage Form in China, 2016-2020
    • 2.3.1 Tablets
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Emtricitabine/Tenofovir Manufacturers in China, 2016-2020

  • 3.1 Analysis of Market Share of Major Emtricitabine/Tenofovir Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Gilead Sciences Inc
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of TRUVADA (Gilead Sciences Inc's Emtricitabine/Tenofovir) in China
  • 3.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Clyke (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Emtricitabine/Tenofovir) in China

4 Prices of Emtricitabine/Tenofovir for Different Manufacturers in China, 2020-2021

  • 4.1 Gilead Sciences Inc (TRUVADA)
  • 4.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Clyke)

5 Prospect of Chinese Emtricitabine/Tenofovir drug Market, 2021-2025

  • 5.1 Influential Factors of Chinese Emtricitabine/Tenofovir Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Emtricitabine/Tenofovir Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Emtricitabine/Tenofovir Tablets Registration in China
  • Chart Sales Value of Emtricitabine/Tenofovir Tablets over the World
  • Chart Sales Value of Emtricitabine/Tenofovir Tablets in China, 2016-2020
  • Chart Sales Value of Emtricitabine/Tenofovir Tablets in China by Region, 2016-2020
  • Chart Sales Volume of Emtricitabine/Tenofovir Tablets in China, 2016-2020
  • Chart Sales Volume of Emtricitabine/Tenofovir Tablets in China by Region, 2016-2020
  • Chart Market Share by Sales Value of Top Emtricitabine/Tenofovir Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of TRUVADA in China, 2016-2020
  • Chart Sales Value and Volume of Clyke in China, 2016-2020
  • Chart Referential Prices of TRUVADA in China, 2020-2021
  • Chart Referential Prices of Clyke in China, 2020-2021
  • Chart Forecast on Sales Value of Emtricitabine/Tenofovir in China, 2021-2025
  • Chart Forecast on Sales Volume of Emtricitabine/Tenofovir in China, 2021-2025